buyModerate cluster of 4
Bain Capital Investors LLC bought $125M of CERE
owner at Cerevel Therapeutics Holdings, Inc.. 5,480,052 shares at an average of $22.81, traded Oct 16, 2023, filed Oct 18, 2023.
Conviction score
50Value
$125M
5,480,052 shares
Holdings after
65,679,781
+9% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +25Trade size$125.0M at market
- +3Relative to holdingsHoldings up 9%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000899243-23-019969, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 16, 2023 | POpen-market purchase Common Stockindirect: See footnotes | +5,480,052 | $22.81 | $125M | 65,679,781 | Oct 18, 2023 |
Related signals
Other insiders at Cerevel Therapeutics Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 23Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $104k 2,506 shares | -14% | |
| 27Weak | Cerevel Therapeutics Holdings, Inc. | John Renger Chief Scientific Officer | $90k 2,161 shares | -25% | |
| 40Moderate | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -95% | |
| 21Weak | Cerevel Therapeutics Holdings, Inc. | Ramiro Sanchez Chief Medical Officer | $425k 10,000 shares | -41% | |
| 35Weak | Cerevel Therapeutics Holdings, Inc. | Kenneth DiPietro Chief Human Resources Officer | $332k 8,000 shares | -24% | |
| 51Moderate | Cerevel Therapeutics Holdings, Inc. | Susan ALTSCHULLER Chief Financial Officer | $572k 13,808 shares | -45% | |
| 39Weak | Cerevel Therapeutics Holdings, Inc. | Scott Akamine Chief Legal Officer | $293k 7,072 shares | -49% | |
| 40Moderate | Cerevel Therapeutics Holdings, Inc. | Mark Bodenrader See Remarks | $327k 7,889 shares | -31% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.